Cantitate/Preț
Produs
Total produse
Vezi coșul
Developing Drug Products in an Aging Society: From Concept to Prescribing de Sven Stegemann

Developing Drug Products in an Aging Society: From Concept to Prescribing: AAPS Advances in the Pharmaceutical Sciences Series, cartea 24

Editat de Sven Stegemann
en Limba Engleză Hardback – 5 dec 2016
This book aims to address the major aspects of future drug product development and therapy for older adults, giving practical guidance for the rational product and clinical development and prescribing of drug products to this ever growing segment of the population. With authors coming from key “aging” markets such as Europe, the USA, China and Japan, the book will provide valuable information for students, scientists, regulators, practitioners, and other healthcare professionals from academia, industry and regulatory bodies.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 108837 lei  6-8 săpt.
  Springer International Publishing – 4 iul 2018 108837 lei  6-8 săpt.
Hardback (1) 151364 lei  6-8 săpt.
  Springer International Publishing – 5 dec 2016 151364 lei  6-8 săpt.

Din seria AAPS Advances in the Pharmaceutical Sciences Series

Preț: 151364 lei

Preț vechi: 184590 lei
-18% Nou

Puncte Express: 2270
Preț estimativ în valută:
28969€ • 30561$ • 24142£

Carte tipărită la comandă

Livrare economică 03-17 ianuarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319430973
ISBN-10: 3319430971
Pagini: 905
Ilustrații: XVIII, 771 p. 96 illus., 85 illus. in color.
Dimensiuni: 155 x 235 x 41 mm
Greutate: 1.28 kg
Ediția:1st ed. 2016
Editura: Springer International Publishing
Colecția Springer
Seria AAPS Advances in the Pharmaceutical Sciences Series

Locul publicării:Cham, Switzerland

Cuprins

Healthcare provision in an aging society: US perspective.- Healthcare provision in an aging society: European perspective.- Healthcare provision in an aging society: Japanese perspective.- Old, Very Old, and Frail.- Age and the process of aging.- Comprehensive Geriatric Assessment.- Patients' clinical characteristics, disease, experience, and perception.- Ethical considerations in performing clinical trials in and for older people.- Patient reported outcomes from a clinical to a therapeutic tool.- Pharmacokinetic and Pharmacodynamic Considerations in the Elderly Population.- The Expectation of a Treatment Model: A framework for adherence and Effectiveness.- Pharmacoepidemiology and pharmacovigilance for safety and efficacy in older people.- Defining patient centric drug product design and its impact on improving safety and effectiveness.- Dosing considerations in older adults.- Oral Drug Product Use in the Elderly Patient Population.- Drug product development for older adults – multiparticulate formulations.- Considerations for topical and transdermal drug delivery in older adults.- Injectable drug delivery for older patients.- Inhalation and Nasal Formulations.- Ophthalmic drug development and the elderly.- Developing drug administration devices for use by older patients.- Manufacturing Platforms for Patient-Centric Drug Products.- Novel Manufacturing Technologies for the Production of Patient-Centric Drug Products.- Prescribing to Older Adults.- Multimorbidity and Polypharmacy.- Vaccination in Older Adults.- Medication Reviews in Older Adults.- The Personalization of Drug therapy for Elderly patients.- Importance of Clinical Nutrition in Therapy to Older Adults.- Managing drug therapy of older patients in primary and secondary care.- Medication adherence and monitoring.- Medication compounding in the provision of drug therapy.- Geriatric Pharmacotherapy: Optimisation through integrated approach in the hospital setting.- European Medicines Agency (EMA): Regulatory perspectives on geriatric medicines.- Views on the Therapeutic Needs of Older Adults.- Future Perspectives in drug therapy of older people.- Opportunities in drug product development in an aging population.

Recenzii

“This book reviews a wide range of topics related to drug development for an aging population … . The intended audience includes practitioners and/or researchers interested in sharing multidisciplinary knowledge, research, and practice expertise to fill existing knowledge gaps in order to improve drug product development for older, very old, multimorbid, and frail individuals.” (Susan K. Romann, Doody's Book Reviews, February, 2017)

Notă biografică

Sven Stegemann is the endowed professor for Patient-Centric Drug Product Design and Manufacturing at the Graz University of Technology and Director of Pharmaceutical Business Development at Capsugel. He is scientist, professor and advocate for multidisciplinary research on patient-centric drug products and affordable medicines. Prof. Stegemann trains the next generation of pharmaceutical scientists. His professional experience spans all stages of drug development and manufacturing--from early development through commercial manufacturing.
His passion and research led him to found the Geriatric Medicine Society e.V. in 2009, a multidisciplinary network that aims to facilitate the development of age-appropriate medicines that older patients can easily and safely take. He also serves in various organizations as chairman or committee member to progress pharmaceutical sciences.
He has established a focus group on patient-centric drug development through the American Association of Pharmaceutical Scientists (AAPS).
As This is integral to improving the quality of life of patients in the future.
He has spoken at innumerable conferences around the world on patient-centric drug delivery, pharmaceutical product development for special patient populations, multiparticulate technologies, adherence, geriatric drug delivery, quality by design and added value generics.

Textul de pe ultima copertă

This book aims to address the major aspects of future drug product development and therapy for older adults, giving practical guidance for the rational product and clinical development and prescribing of drug products to this ever growing segment of the population. With authors coming from key “aging” markets such as Europe, the USA, China and Japan, the book will provide valuable information for students, scientists, regulators, practitioners, and other healthcare professionals from academia, industry and regulatory bodies.

Caracteristici

Focuses on drug product development and prescribing for older patients from a multidisciplinary and global perspective Provides practical guidelines for developing drugs for this population Discusses regulatory pathways for medicines for older patients Includes supplementary material: sn.pub/extras